Showing results (3641-3650 of 6,795) with videos related to
Sort By:
Pageof 680
Clinical Therapeutics|June 29, 2004
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trialGiuseppe Derosa, Arrigo F G Cicero, Antonio Gaddi, et al.Clinical Therapeutics|August 5, 2004
Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?Martin WehlingClinical Therapeutics|June 11, 2004
Once-daily budesonide aqueous nasal spray for allergic rhinitis: a reviewBrett E StanalandClinical Therapeutics|June 11, 2004
A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertensionThomas K Mundorf, Takahiro Ogawa, Hiroaki Naka, et al.Clinical Therapeutics|June 11, 2004
Development and validation of the insulin treatment satisfaction questionnaireRoger T Anderson, Soren E Skovlund, David Marrero, et al.Clinical Therapeutics|June 11, 2004
Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitusAlison L Supina, Lisa M Guirguis, Sumit R Majumdar, et al.Clinical Therapeutics|July 1, 1992
Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infectionsM J Huston, J R LentinoClinical Therapeutics|July 21, 2004
Is there a place for epoetin alfa in managing anemia during critical illness?Marlea Givens, Marc LapointeClinical Therapeutics|March 25, 2004
Stress-related mucosal disease: risk factors and prophylactic therapyMitchell J SpirtClinical Therapeutics|January 30, 2004
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidenceLuis M Ruilope, Julian SeguraPageof 680